title: Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.
abstract: Growth hormone insensitivity syndrome (GHI) or insulin-like growth factor-1 (IGF-1) deficiency (IGFD) is characterized by deficit of IGF-1 production due to alteration of response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH receptor or IGF-1 gene and patients affected showed no response to GH therapy. The only treatment is recombinant IGF-1 (mecasermin), which has been available since 1986, but approved in the United States by the US Food and Drug Administration only in 2005 and in Europe by the European Medicines Agency in 2007. To date, few studies are available on long-term treatment with mecasermin in IGFD patients and some of them have a very small number of subjects. In this review we discuss briefly clinical features of severe primary IGFD, laboratory findings, and indications for treatment. Results of long-term therapy with rhIGF1 (mecasermin) in patients affected by severe primary IGFD and possible side effects are explained.
authors.affiliation: Endocrinology Unit, "Bambino Gesù" Children's Hospital-IRCCS, Rome, Italy.
authors.forename: Danilo
authors.initials: D
authors.lastname: Fintini
authors.forename: Claudia
authors.initials: C
authors.lastname: Brufani
authors.forename: Marco
authors.initials: M
authors.lastname: Cappa
references.citation: Horm Res. 2006;65 Suppl 1:15-20
references.pmid: 16508329
references.citation: J Clin Endocrinol Metab. 2001 Nov;86(11):5176-83
references.pmid: 11701674
references.citation: Clin Endocrinol (Oxf). 2004 Feb;60(2):163-8; discussion 161-2
references.pmid: 14725676
references.citation: J Pediatr. 2007 Jan;150(1):7-11
references.pmid: 17188604
references.citation: N Engl J Med. 1987 Jul 16;317(3):137-40
references.pmid: 3299085
references.citation: Curr Opin Investig Drugs. 2006 Apr;7(4):371-80
references.pmid: 16625824
references.citation: J Clin Endocrinol Metab. 2004 Mar;89(3):1031-44
references.pmid: 15001582
references.citation: Adv Ther. 2009 Jan;26(1):40-54
references.pmid: 19198769
references.citation: Growth Horm IGF Res. 2006 Oct-Dec;16(5-6):277-89
references.pmid: 17101287
references.citation: J Clin Endocrinol Metab. 2001 Apr;86(4):1504-10
references.pmid: 11297575
references.citation: Horm Res. 2003;60(5):237-46
references.pmid: 14614229
references.citation: Eur J Pediatr. 1980 Jun;134(1):79-83
references.pmid: 7408914
references.citation: J Clin Endocrinol Metab. 2007 Mar;92(3):902-10
references.pmid: 17192294
references.citation: J Clin Endocrinol Metab. 1995 Apr;80(4):1393-8
references.pmid: 7536209
references.citation: J Bone Miner Res. 1998 Mar;13(3):415-21
references.pmid: 9525342
references.citation: Acta Paediatr Suppl. 1994 Apr;399:137-9
references.pmid: 7949599
references.citation: Endocr Rev. 2007 Feb;28(1):20-47
references.pmid: 16931767
references.citation: Horm Res. 1999;51(3):128-34
references.pmid: 10461018
references.citation: J Clin Endocrinol Metab. 2008 Jan;93(1):10-8
references.pmid: 18165284
references.citation: Endocr Dev. 2009;14:135-42
references.pmid: 19293580
references.citation: Clin Biochem. 2005 Jul;38(7):659-66
references.pmid: 15885685
references.citation: Metabolism. 1995 Oct;44(10 Suppl 4):113-8
references.pmid: 7476303
references.citation: Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):395-407
references.pmid: 16932322
references.citation: Isr J Med Sci. 1988 Feb;24(2):75-9
references.pmid: 3356536
references.citation: Curr Opin Pediatr. 2007 Aug;19(4):458-64
references.pmid: 17630612
references.citation: Trends Endocrinol Metab. 2007 May-Jun;18(4):134-41
references.pmid: 17391978
references.citation: Endocr Dev. 2005;9:100-106
references.pmid: 15879692
references.citation: J Pediatr Endocrinol Metab. 2003 Apr-May;16(4):509-20
references.pmid: 12793602
references.citation: J Clin Endocrinol Metab. 1999 Dec;84(12):4436-43
references.pmid: 10599699
references.citation: Endocr Rev. 2001 Feb;22(1):53-74
references.pmid: 11159816
references.citation: Lancet. 1992 May 23;339(8804):1258-61
references.pmid: 1349669
references.citation: J Clin Endocrinol Metab. 2004 May;89(5):2271-4
references.pmid: 15126552
references.citation: J Endocrinol Invest. 2007 May;30(5):417-20
references.pmid: 17598975
references.citation: J Clin Endocrinol Metab. 1997 Feb;82(2):629-33
references.pmid: 9024266
references.citation: N Engl J Med. 1996 Oct 31;335(18):1363-7
references.pmid: 8857020
references.citation: J Clin Endocrinol Metab. 2006 Apr;91(4):1246-53
references.pmid: 16403822
references.citation: Acta Paediatr Suppl. 1994 Apr;399:112-4
references.pmid: 7949594
references.citation: J Pediatr Endocrinol Metab. 1999 Apr;12 Suppl 1:231-49
references.pmid: 10698588
references.citation: J Clin Endocrinol Metab. 2003 Oct;88(10):4586-9
references.pmid: 14557426
references.citation: N Engl J Med. 2004 Feb 5;350(6):570-7
references.pmid: 14762184
references.citation: J Clin Endocrinol Metab. 1993 Jul;77(1):273-80
references.pmid: 7686916